Editorial: a strategy to optimise the business value of Intellectual Property
by Michael J. Lynskey
International Journal of Biotechnology (IJBT), Vol. 8, No. 3/4, 2006

Abstract: In this paper, we suggest that, although Intellectual Property (IP) is an intangible asset of a firm, it is now treated effectively as if it were a tangible product. It is also a strong determinant of the success of biotechnology firms, since it is assessed carefully by investors, potential partners and acquirers, who understand that the value of a biotechnology firm is ultimately related to the sophistication with which it operates in the IP arena. As such, we propose that a viable corporate strategy should be one that recognises IP as an activity, like research and development, as part of a value chain, and which can only create value in combination with other production factors. A well-defined, cohesive strategy should deliver a balanced and effective IP production process, to ensure that what is protected and leveraged by firms is of real business value and has the best chance of being licensed.

Online publication date: Wed, 15-Mar-2006

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com